Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience
Cells · 18.06.2026 · 15 (12) · 1104
DOI: 10.3390/cells15121104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 18.06.2026. Verfasst von Igor Samatoshenkov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Endovascular Surgery, Klinik Mittelbaden Rastatt-Forbach, 76437 Rastatt, Germany. Hauptthemen laut MEDLINE: Genetic Therapy, Ischemia, Angiogenesis, Lower Extremity. Die Arbeit nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kazan Federal University Strategic Academic Leadership Program.
Abstract (Originalsprache)
Peripheral arterial disease and critical limb-threatening ischemia remain major clinical challenges, particularly in patients who are not candidates for surgical or endovascular revascularization. These limitations have stimulated extensive investigation into therapeutic angiogenesis using gene therapy approaches. This review summarizes experimental and clinical studies employing non-viral and viral gene delivery systems for the transfer of angiogenic factors, including VEGF, FGF-2, HGF, HIF-1α, and SDF-1. Particular attention is given to vector platforms, study design, patient populations, clinical endpoints, and safety outcomes reported in preclinical investigations and clinical trials. Although several studies demonstrated biological activity and favorable safety profiles, randomized trials such as RAVE and TAMARIS failed to demonstrate consistent and significant clinical efficacy. These findings emphasize the translational challenges associated with therapeutic angiogenesis and highlight the persistent gap between promising preclinical data and clinical outcomes in humans. Future progress in the field will likely depend on improved vector engineering, tissue-specific and regulated gene expression systems, optimized delivery strategies, and the integration of gene therapy with emerging regenerative technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Vascular and Endovascular Surgery, Klinik Mittelbaden Rastatt-Forbach, 76437 Rastatt, Germany.
- Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia.
- SAHI Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, 420138 Kazan, Russia.
- Division of Medical and Biological Sciences, Tatarstan Academy of Sciences, 420111 Kazan, Russia.
- Department of Histology, Cytology and Embryology, Kazan State Medical University, 420012 Kazan, Russia.
ORCID-Profile: Igor Samatoshenkov, Albert Rizvanov, Yana Mukhamedshina
Förderung
- Kazan Federal University Strategic Academic Leadership Program
Zitieren
APA
Samatoshenkov, I., Zakirova, E., Samatoshenkova, J., Rizvanov, A., & Mukhamedshina, Y. (2026). Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience. Cells, 15(12), 1104. https://doi.org/10.3390/cells15121104
Vancouver
Samatoshenkov I, Zakirova E, Samatoshenkova J, Rizvanov A, Mukhamedshina Y. Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience. Cells. 2026;15(12):1104. doi:10.3390/cells15121104
BibTeX
@article{Samatoshenkov2026,
author = {Samatoshenkov, Igor and Zakirova, Elena and Samatoshenkova, Julia and Rizvanov, Albert and Mukhamedshina, Yana},
title = {Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience},
journal = {Cells},
year = {2026},
volume = {15},
number = {12},
pages = {1104},
doi = {10.3390/cells15121104}
}
EUVIMED